Questions to Ask Before Selecting Best Online GLP-1 Providers

Ten questions settle it. Who prescribes and where are they licensed. Is the medication brand or compounded. Which pharmacy fills it. What does the fee include. Does price change with dose. Who answers side-effect messages and how fast. What happens if a dose is paused. How are refills timed. How does cancellation work. Will records be released.

Ask these before the intake form, not after

Most online weight programs put payment before information. The intake questionnaire arrives first, a charge follows, and the operational details surface only once a person is inside the system. Sending questions to support before starting inverts that order, and the speed and specificity of the reply is itself a data point about how the service handles a clinical message later.

The questions below apply across the field, whether the service is a cash-pay telehealth platform like Ro, Hims and Hers, Found, Henry Meds, Mochi, or Eden, a coaching-led program such as Noom or Calibrate, or a manufacturer channel like LillyDirect or NovoCare Pharmacy. The answers differ sharply, which is the point.

Those same questions also expose how differently the named services answer them. Ro and Hims and Hers tend to publish policies while holding full pricing until intake, Henry Meds and Eden post per-strength figures, and a provider like HealthRX sets out which GLP-1 medications it carries so the clinical and cost questions can be put against a specific offer. The value is in the contrast, since two services describing themselves in nearly identical language often diverge the moment these questions are asked.

Questions about the clinician

Start with the person who signs. Ask for a name and credential, and for the state the license is held in. Ask whether that clinician reads the intake responses or whether an algorithm screens first. Ask whether there is a live visit by video or phone, or whether the whole encounter runs asynchronously through text.

Asynchronous care is legitimate and widely used, but it changes what a person should expect. Clinical guidance on obesity pharmacotherapy treats medication as one part of a supervised plan, including screening for contraindications and follow-up on tolerance and response. A program with no mechanism for a real conversation when something goes wrong has removed a part of that plan.

Questions about the medication

Ask directly whether the product is an FDA-approved brand medication or a compounded preparation. Compounded semaglutide and compounded tirzepatide are not FDA-approved, and the FDA has published concerns about unapproved GLP-1 products sold for weight loss. A service should answer this in one sentence. Hedging is the answer.

Then ask which molecule and at what concentration, whether the dose is expressed in milligrams or in syringe units, and what the maximum strength available through the program is. That last question catches a real problem: some programs cap below the strengths used in the pivotal trials, so a person who needs to escalate ends up having to change providers mid-course.

Question	Answer that holds up	Answer that should stop you
Who writes the prescription?	A named clinician licensed in your state	“Our licensed medical team”
Brand or compounded?	A direct statement of which, in writing	“Same active ingredient as the brand”
Which pharmacy dispenses?	Pharmacy named, with its licensing state	“A partner pharmacy network”
What is the maximum dose offered?	A stated ceiling and the price at that strength	“That is determined later”
How fast is a side-effect message answered?	A stated window and who replies	“Support is available 24/7”
How do I cancel?	A described process with notice period and refund terms	Cancellation only by phone during limited hours

Questions about what happens when something goes wrong

Nausea, vomiting, and gastrointestinal upset are the predictable early effects of these drugs, and they are the usual reason people stop. So ask what happens at week three if the starting dose is not tolerated. Can the dose be held or reduced without losing a prepaid month. Who makes that call. How long does the change take to reach the pharmacy.

Ask the same about a missed shipment and about a dose skipped for travel or illness. These are ordinary events across a year of treatment, and the difference between programs is almost entirely in how routinely they handle them rather than in whether they can.

Questions about money and about leaving

Two money questions cover most of it: what is the price at the strength you would realistically reach by month six, and what changes when any introductory period ends. Published pricing makes both answerable in advance. Cash-pay compounded programs including Henry Meds, Eden, Mochi, and FormBlends post per-month figures for their strengths, while other platforms disclose the full schedule only after intake, which is worth knowing before spending time on a questionnaire.

The exit questions are the ones people skip and later regret. What is the notice period. Are prepaid months refundable. Does cancellation stop the medication immediately or at the end of a cycle. And will the program release visit notes and the dispensing history to another clinician on request, since continuity depends on that record traveling.

Frequently asked questions

Is it unusual to ask a telehealth company this many questions?

No, and support teams field them regularly. A year of GLP-1 treatment is a significant commitment of money and clinical attention. The reply time and the willingness to answer plainly tell you as much about how the service operates as the answers themselves do.

What if the answers arrive only as template responses?

Templates are fine for pricing and logistics questions. They are a warning sign on clinical ones. If a question about holding a dose for intolerance returns generic marketing copy, that is a preview of what a real side-effect message will produce once treatment is underway.

Does the maximum available dose really matter at the start?

It can. Trial evidence for both molecules involves stepwise escalation to target strengths over months, and maintenance data show continued treatment matters for holding results. Discovering a program’s ceiling in month five, once the routine is established, is a harder problem than checking it in week one.

How should someone weigh a coaching-led program against a medication-only service?

By whether the coaching is used. Behavioral support has measurable value for some people and none for those who ignore it, and it usually carries a fee either way. The honest question is not whether coaching helps in general but whether it will be opened.

Which single question is the most revealing?

The cancellation question. It is the only one where the company’s interest and the customer’s interest diverge outright, so the clarity of the answer says a great deal. Programs that describe the process precisely, including refunds on prepaid months, tend to be straightforward elsewhere.